4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      In vitro and in vivo Anti‐Toxoplasma activity of Dracocephalum kotschyi essential oil

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Toxoplasma gondii is a zoonotic parasite of worldwide importance, responsible for toxoplasmosis in homeotherms. Although treatment options are readily available, most drugs often cause serious side effects. Extracts of Dracocephalum kotschyi ( D. kotschyi) have shown significant pharmacological activity against various parasites, viruses, and bacteria. In this study, we evaluated the anti‐ T. gondii activity in vitro and in vivo of D. kotschyi essential oil. The thiazolyl blue tetrazolium bromide (MTT) method was used to assess the anti‐ T. gondii activity and cytotoxicity of the essential oil. The presence of T. gondii was observed by Giemsa staining, and the viability was evaluated by the trypan blue staining method. Furthermore, the survival rate of acutely infected mice was evaluated by intraperitoneal injecting of the essential oil (50, 100, and 200 mg kg −1 day −1) for five days after infection with 2 × 10 4 tachyzoites. Essential oil, negative, and positive controls that showed the best toxoplasmacidal activity were assayed in triplicate at each concentration. The essential oil exhibited the highest anti‐ Toxoplasma activity with a half‐maximal inhibitory concentration (IC 50) of 9.94 ± 0.38 µg, with a selectivity index of 2.463. On Vero cells, the CC 50 of the oil was 24.49 ± 0.96 µg and exhibited a significant anti‐ Toxoplasma activity. Moreover, the treatment by essential oil significantly increased the survival rate compared to untreated infected control. In conclusion, the essential oil might be a useful compound, and with more testing, it may be an excellent alternative to standard chemical drugs in the treatment of toxoplasmosis.

          Abstract

          The results obtained in this study attribute to the essential oil of D. kotschyi, inhibitory activity against T. gondii, without toxicity to the host.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

          A tetrazolium salt has been used to develop a quantitative colorimetric assay for mammalian cell survival and proliferation. The assay detects living, but not dead cells and the signal generated is dependent on the degree of activation of the cells. This method can therefore be used to measure cytotoxicity, proliferation or activation. The results can be read on a multiwell scanning spectrophotometer (ELISA reader) and show a high degree of precision. No washing steps are used in the assay. The main advantages of the colorimetric assay are its rapidity and precision, and the lack of any radioisotope. We have used the assay to measure proliferative lymphokines, mitogen stimulations and complement-mediated lysis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice

            SUMMARY Primary Toxoplasma gondii infection is usually subclinical, but cervical lymphadenopathy or ocular disease can be present in some patients. Active infection is characterized by tachyzoites, while tissue cysts characterize latent disease. Infection in the fetus and in immunocompromised patients can cause devastating disease. The combination of pyrimethamine and sulfadiazine (pyr-sulf), targeting the active stage of the infection, is the current gold standard for treating toxoplasmosis, but failure rates remain significant. Although other regimens are available, including pyrimethamine in combination with clindamycin, atovaquone, clarithromycin, or azithromycin or monotherapy with trimethoprim-sulfamethoxazole (TMP-SMX) or atovaquone, none have been found to be superior to pyr-sulf, and no regimen is active against the latent stage of the infection. Furthermore, the efficacy of these regimens against ocular disease remains uncertain. In multiple studies, systematic screening for Toxoplasma infection during gestation, followed by treatment with spiramycin for acute maternal infections and with pyr-sulf for those with established fetal infection, has been shown to be effective at preventing vertical transmission and minimizing the severity of congenital toxoplasmosis (CT). Despite significant progress in treating human disease, there is a strong impetus to develop novel therapeutics for both the acute and latent forms of the infection. Here we present an overview of toxoplasmosis treatment in humans and in animal models. Additional research is needed to identify novel drugs by use of innovative high-throughput screening technologies and to improve experimental models to reflect human disease. Such advances will pave the way for lead candidates to be tested in thoroughly designed clinical trials in defined patient populations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Congenital Toxoplasmosis.

              Toxoplasmosis is caused by infection with the parasite Toxoplasma gondii. It is one of the most common parasitic infections in humans and is most typically asymptomatic. However, primary infection in a pregnant woman can cause severe and disabling disease in the developing fetus. Recent developments have included increased understanding of the role of parasite genotype in determining infectivity and disease severity. Risk factors for acquisition of infection have been better defined, and the important role of foodborne transmission has been further delineated. In addition, strategies have emerged to decrease mother-to-child transmission through prompt identification of acutely infected pregnant women followed by appropriate treatment. Refined diagnostic tools, particularly the addition of immunoglobulin G avidity testing, allow for more accurate timing of maternal infection and hence better decision making during pregnancy. Congenitally infected children can be treated, beginning in utero and continuing through the first year of life, to ameliorate the severity of disease. However, despite these many advances in our understanding of congenital toxoplasmosis prevention and treatment, significant areas of study remain: we need better drugs, well defined strategies for screening of pregnant women, improved food safety, and improved diagnostic tests.
                Bookmark

                Author and article information

                Contributors
                faham.khamesipour@yahoo.com
                mrazavi@shirazu.ac.ir
                Journal
                Food Sci Nutr
                Food Sci Nutr
                10.1002/(ISSN)2048-7177
                FSN3
                Food Science & Nutrition
                John Wiley and Sons Inc. (Hoboken )
                2048-7177
                12 November 2020
                January 2021
                : 9
                : 1 ( doiID: 10.1002/fsn3.v9.1 )
                : 522-531
                Affiliations
                [ 1 ] Department of Pathobiology School of Veterinary Medicine Shiraz University Shiraz Iran
                [ 2 ] Department of Parasitology and Mycology Skin Diseases and Leishmaniasis Research Center School of Medicine Isfahan University of Medical Sciences Isfahan Iran
                [ 3 ] Department of Pharmacognosy Isfahan Pharmaceutical Sciences Research Center Isfahan University of Medical Sciences Isfahan Iran
                Author notes
                [*] [* ] Correspondence

                Faham Khamesipour and Seyed Mostafa Razavi, Department of Pathobiology, School of Veterinary Medicine, Shiraz University, P.O. Box: 71345 1731, Shiraz, Iran.

                Email: faham.khamesipour@ 123456yahoo.com ; mrazavi@ 123456shirazu.ac.ir

                Author information
                https://orcid.org/0000-0003-0678-2528
                Article
                FSN32021
                10.1002/fsn3.2021
                7802582
                33473313
                876e70c4-2703-436f-9ee9-6da3a7a967a5
                © 2020 The Authors. Food Science & Nutrition published by Wiley Periodicals LLC

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 12 September 2020
                : 31 October 2020
                : 02 November 2020
                Page count
                Figures: 5, Tables: 3, Pages: 10, Words: 6803
                Categories
                Original Research
                Original Research
                Custom metadata
                2.0
                January 2021
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.6 mode:remove_FC converted:12.01.2021

                anti‐t. gondii activity,cytotoxicity,dracocephalum kotschyi,essential oil,toxoplasma gondii

                Comments

                Comment on this article